Ribozymes for treating hepatitis C
US6107028A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 15, 1996 |
| Grant date | Aug 22, 2000 |
| Priority date | — |
| Expiry date | May 15, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of inhibiting hepatitis C virus RNA replication or expression is provided. The method consists of introducing two or more ribozymes specific for hepatitis C virus RNA into a cell infected with hepatitis C virus. The ribozymes specific for hepatitis C virus RNA can specifically cleave hepatitis C RNA in a HCV 5' non-coding sequence, the capsid sequence, the NS-5 sequence or any other conserved region of the hepatitis C RNA. The ribozymes can also be selected so as to be specific for opposite strands of the virus genome. A method of inhibiting hepatitis C virus RNA replication or expression is also provided which consists of introducing into a cell infected with hepatitis C virus at least one ribozyme specific for hepatitis C virus which is selected from the group consisting of GGGAGGTCTCGTAGA [SEQ ID NO: 1], GCACCATGAGCACGA [SEQ ID NO: 2], CCCACAGGACGTCAA [SEQ ID NO: 3], CAACCGTCGCCCACA [SEQ ID NO: 4], TAAACCTCAAAGAAA [SEQ ID NO: 5] GTAAGGTCATCGATA [SEQ ID NO: 6]. Compositions consisting of two or more ribozymes specific for hepatitis C virus RNA is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.